FDA says Opioids may be found in Novartis OTC drugs
The FDA has released an advisory regarding the Novartis recall due to the mixed bottling of products. While previous reports suggested that the OTC drugs NoDoz, Excedrin, Bufferin and Gas-X had simply been mixed with each other, the FDA now is warning patients that high-powered, prescription-only opioid drugs may have found their way into Novartis OTC packaging.
The FDA said these “potent medications” include nine opioids: Opana ER, Opana, Oxymorphone, Percocet, Percodan, Endocet, Endodan, Morphine Sulfate and Zydone.
Analysts say Novartis stands to lose $560 million in sales over the next 12 months, and potentially $1.1 billion globally.
Novartis noted that Gas-X is no longer on the list of products involved in the bottling mishaps.